CIC
INO icon

Carnegie Investment Counsel’s Inovio Pharmaceuticals INO Stock Holding History

Carnegie Investment Counsel’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-208
Closed -$8K – 204
2013
Q2 		$8K Buy
+208
New +$6.3K ﹤0.01% 190

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carnegie Investment Counsel's INO Position: Q3 2013 in Review

Carnegie Investment Counsel sold out of Inovio Pharmaceuticals (INO) in Q3 2013, closing a stake of 208 shares — an estimated $8K sold.

Carnegie Investment Counsel first reported a position in INO in Q2 2013 and held it in 1 quarter. The position peaked at $8K in Q2 2013. 35 funds tracked by Wall St. Rank hold INO as of Q3 2013.

  • Carnegie Investment Counsel reported no remaining Inovio Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Carnegie Investment Counsel sold 208 Inovio Pharmaceuticals shares in Q3 2013, an estimated $8K.
  • Carnegie Investment Counsel first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Carnegie Investment Counsel's Inovio Pharmaceuticals position peaked at $8K in Q2 2013.
  • 35 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2013.

Based on Carnegie Investment Counsel's 13F filing for Q3 2013, filed 8 Oct 2013.